Endogenous PGD2 acting on DP2 receptor counter regulates Schistosoma mansoni infection-driven hepatic granulomatous fibrosis
PLOS Pathogens · 2024
DOI: 10.1371/journal.ppat.1011812 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Giovanna N Pezzella-Ferreira und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Inflamação, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Prostaglandin D2, Schistosomiasis mansoni, Receptors, Prostaglandin, Schistosoma mansoni. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico (Brazil), Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro.
Abstract (Originalsprache)
Identifying new molecular therapies targeted at the severe hepatic fibrosis associated with the granulomatous immune response to Schistosoma mansoni infection is essential to reduce fibrosis-related morbidity/mortality in schistosomiasis. In vitro cell activation studies suggested the lipid molecule prostaglandin D 2 (PGD 2 ) as a potential pro-fibrotic candidate in schistosomal context, although corroboratory in vivo evidence is still lacking. Here, to investigate the role of PGD 2 and its cognate receptor DP2 in vivo , impairment of PGD 2 synthesis by HQL-79 (an inhibitor of the H-PGD synthase) or DP2 receptor inhibition by CAY10471 (a selective DP2 antagonist) were used against the fibrotic response of hepatic eosinophilic granulomas of S . mansoni infection in mice. Although studies have postulated PGD 2 as a fibrogenic molecule, HQL-79 and CAY10471 amplified, rather than attenuated, the fibrotic response within schistosome hepatic granulomas. Both pharmacological strategies increased hepatic deposition of collagen fibers — an unexpected outcome accompanied by further elevation of hepatic levels of the pro-fibrotic cytokines TGF-β and IL-13 in infected animals. In contrast, infection-induced enhanced LTC 4 synthesis in the schistosomal liver was reduced after HQL-79 and CAY10471 treatments, and therefore, inversely correlated with collagen production in granulomatous livers. Like PGD 2 -directed maneuvers, antagonism of cysteinyl leukotriene receptors CysLT1 by MK571 also promoted enhancement of TGF-β and IL-13, indicating a key down-regulatory role for endogenous LTC 4 in schistosomiasis-induced liver fibrosis. An ample body of data supports the role of S . mansoni -driven DP2-mediated activation of eosinophils as the source of LTC 4 during infection, including: (i) HQL-79 and CAY10471 impaired systemic eosinophilia, drastically decreasing eosinophils within peritoneum and hepatic granulomas of infected animals in parallel to a reduction in cysteinyl leukotrienes levels; (ii) peritoneal eosinophils were identified as the only cells producing LTC 4 in PGD 2 -mediated S . mansoni -induced infection; (iii) the magnitude of hepatic granulomatous eosinophilia positively correlates with S . mansoni -elicited hepatic content of cysteinyl leukotrienes, and (iv) isolated eosinophils from S . mansoni -induced hepatic granuloma synthesize LTC 4 in vitro in a PGD 2 /DP2 dependent manner. So, our findings uncover that granulomatous stellate cells-derived PGD 2 by activating DP2 receptors on eosinophils does stimulate production of anti-fibrogenic cysLTs, which endogenously down-regulates the hepatic fibrogenic process of S . mansoni granulomatous reaction — an in vivo protective function which demands caution in the future therapeutic attempts in targeting PGD 2 /DP2 in schistosomiasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratório de Inflamação, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
- Departamento de Ciências da Natureza, Instituto de Aplicação Fernando Rodrigues da Silveira, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
- Laboratório de Imunofarmacologia e Inflamação, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
- Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
ORCID-Profile: Bruno L Diaz
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (Brazil)
- Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Pezzella-Ferreira, G. N., Pão, C. R. R., Bellas, I., Luna-Gomes, T., Muniz, V. S., Paiva, L. A., Amorim, N. R. T., Canetti, C., Bozza, P. T., Diaz, B. L., & Bandeira-Melo, C. (2024). Endogenous PGD2 acting on DP2 receptor counter regulates Schistosoma mansoni infection-driven hepatic granulomatous fibrosis. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011812
Vancouver
Pezzella-Ferreira GN, Pão CRR, Bellas I, Luna-Gomes T, Muniz VS, Paiva LA, et al. Endogenous PGD2 acting on DP2 receptor counter regulates Schistosoma mansoni infection-driven hepatic granulomatous fibrosis. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1011812
BibTeX
@article{PezzellaFerreira2024,
author = {Pezzella-Ferreira, Giovanna N and Pão, Camila R R and Bellas, Isaac and Luna-Gomes, Tatiana and Muniz, Valdirene S and Paiva, Ligia A and Amorim, Natalia R T and Canetti, Claudio and Bozza, Patricia T and Diaz, Bruno L and Bandeira-Melo, Christianne},
title = {Endogenous PGD2 acting on DP2 receptor counter regulates Schistosoma mansoni infection-driven hepatic granulomatous fibrosis},
journal = {PLOS Pathogens},
year = {2024},
doi = {10.1371/journal.ppat.1011812}
}
EUVIMED